The biggest barrier to the development of effective, cheap AIDS drugs is the extreme mutability of HIV (human immunodeficiency virus -- the cause of AIDS). Because HIV quickly mutates to become resistant to any one drug, current AIDS treatment involves multiple drug cocktails, which are very expensive and require demanding treatment schedules. A different approach entirely is to develop drugs that target the more stable proteins of the patient instead of the constantly mutating proteins of the virus.
It is known that HIV originated in chimpanzees, our closest living relatives. When HIV first entered chimpanzee populations, susceptible chimpanzees were killed, while the small minority of resistant chimpanzees survived. The virus has remained in chimpanzee populations, selecting for chimpanzee adaptations that today provide an ironclad means of holding the virus at bay in nature, in spite of the astonishing ability of the virus to mutate. While humans succumb to progressive disease after infection with HIV-1 (AIDS), chimpanzees do not. Thus, Evolutionary Genomics studies adapted chimpanzee proteins looking for new targets for human AIDS drugs.
Evolutionary Genomics scientists discovered that three ICAM (intercellular cell adhesion molecule) proteins, called ICAM 1, ICAM 2, and ICAM 3, have all undergone intensive adaptive evolution in chimpanzees. Genes that have undergone such adaptive evolution are rare; in fact, more than 99 percent of mammalian genes that have been studied by others do not display evidence of adaptive evolution. Thus, these three genes are distinctly different. Yet, as in humans, the ICAM 1, 2, and 3 proteins carry out other important cell to cell contact functions in chimpanzees, so they cannot be too dramatically altered, or these other functions would be negatively affected. For example, EG scientists have found that the changes in the chimpanzee version of ICAM 1 appear in locations where they likely modulate rather than abolish the functions of ICAM 1.
Cell to cell contact is critical to the progression of infection by HIV-1.
HIV-1 appears to co-opt the functions of cell adhesion molecules, particularly ICAMs, to enhance viral infection and transmission. The ICAM proteins are also selectively incorporated by HIV into its virus coat as it commandeers human cell capacities and redirects them to producing more virus. By incorporating the ICAM proteins into its virus coat, HIV-1 becomes more infectious, perhaps even to cells in the body that normally keep the virus out. The adaptive changes in chimpanzee ICAMs thus may slow cell to cell transfer of HIV and/or thwart the increased infectivity of HIV decorated with chimpanzee ICAMs.
Dr. Walter Messier, chief technology officer of evolutionary genomics and senior author of the study said, Once we know the specific effects of chimpanzee adaptive changes, we can screen for small molecule compounds that provide infected humans the same disease protection as seen in the chimpanzee.
SOURCE: Evolutionary Genomics, LLC